Recollective Baseline Better Decisions From Deeper Insights Until now there hasn't been an easy and accessible way to ask and understand why people act and think as they do. Professional researchers answer this question by examining behaviours and emotional reactions through in-person focus groups. You may gauge this type of learning by hosting meetings, sending emails or chatting by the water cooler. Recollective Baseline brings this process online and gives you access to the same tool the Pros use. Better Gather & synthesize data in a quick and structured manner. Faster The platform is fully mobile and responses are viewed in real time. Cheaper It's efficient, saves time and is free for up to 50 participants. Breaking Eroom’s Law Early in the last decade, researchers at Sanford Bernstein published "Eroom’s Law’— Moore’s Law in reverse — that the all-in cost of R&D on new drugs approved by the US FDA had risen exponentially for 60 years (Nat. Rev. Drug Discov. 11, 191–200; 2012). Among the potential contributing factors underlying the trend, the authors highlighted a progressively higher bar for improvements over existing therapies (the ‘better than the Beatles’ problem) and a progressive lowering of risk tolerance by regulatory agencies (the ‘cautious regulator’ problem). However, as the researchers posited might happen, about the same time Eroom’s Law was published, it was already being broken. Breaking the law: how and why Starting around 2010, the trend line changed, with a net result of an additional 0.7 new molecular entity (NME) launches per US$1 billion of R&D spending per year by 2018 (P <1.5 × 10−10) (Fig. 1a). What changed? Better information. Better use of information. Conclusions Acknowledgements
Mural.ly - Visual Collaboration for Creative People Digital Twins – A Way Forward To Unlock the Pivotal Hidden Signals To Increase ROI in Drug Discovery? Considering the risk of false positives and false negatives associated with biomarkers, it’s important to understand the scientific correlation between the biomarker and corresponding clinical outcome to know whether a biomarker is reliable. A three-arm trial studying pertussis vaccines in Sweden provides a good example of a false positive case: Subjects received a two-component acellular DTP vaccine, a five-component acellular vaccine, or a placebo. The five-component acellular vaccine reduced pertussis in 85 percent of the cases, while the two-component vaccine only provided 58 percent reduction. When comparing the two vaccines, although the five-component vaccine had overall superior efficacy, the two-component vaccine had superior effects on two major biomarkers, favoring the two-component vaccine. Potential false negative clinical outcomes could be avoided by understanding and developing digital models from data obtained from measuring biomarkers and from clinical pathways.
coWonder Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 April 29, 2020 Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 -- Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of Remdesivir -- --(BUSINESS WIRE)--Apr. 29, 2020-- (Nasdaq: GILD) today announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. “Unlike traditional drug development, we are attempting to evaluate an investigational agent alongside an evolving global pandemic. Remdesivir is not yet licensed or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19. In this study, the time to clinical improvement for 50 percent of patients was 10 days in the 5-day treatment group and 11 days in the 10-day treatment group. Clinical outcomes varied by geography. About
Coffitivity - Increase Your Creativity! Health technology report | ATSE For several decades, Australia’s healthcare system has increased life expectancy and improved quality of life. Now healthcare in Australia is under strain, challenged by an ageing population, chronic illnesses, evolving consumer behaviour, and changes in the type and frequency of emerging diseases. The digital revolution has readied Australia for a more rounded approach to wellness, and a radical shift to preventive healthcare. In the decade to 2030, we predict: Click here for media information.